5 Biomedical Stocks That Are Expected To Surge

At Zacks, we understand that investors are constantly searching for growth opportunities. Every investor struggles with balancing risk and reward when choosing their investments. Biomedical companies are known to offer large capital gains and growth prospects, yet they do not always come to fruition.

However, President Donald Trump has stated on multiple occasions that he plans to eliminate restrictions on drug development for the FDA. This policy would positively affect biomedical companies, as their products would reach the open market more easily and frequently. Certain biomedical companies will pose a stronger investment as the FDA revises their drug development standards.

With the promise of regulatory reform on the horizon, investors have been excited about the biomedical space throughout the year. If you want to add some to your portfolio, check out these 5 biomedical stocks that are primed to skyrocket here:  

1. Regeneron Pharmaceuticals, Inc. (REGN - Free Report)

Regeneron Pharmaceuticals is a biopharmaceutical company that develops and intends to commercialize drugs for the treatment of serious medical conditions. Regeneron touts a RoE of 22.99% and Net Margin of 19.34, both of which compare favorably to the industry. Additionally, its share price has increased by 48.85% over the past year. And since the company scored a “B” grade for Growth, we expect the company to continue to grow and outperform the market.

Also, Regeneron reported a Cash Flow per share of $10.05, which towers over the industry average. This means that Regeneron is successfully utilizing shareholder equity in a much more effective manner than its competitors. Regeneron Pharmaceuticals currently sports a Zacks Rank #1 (Strong Buy).

2. Geron Corporation (GERN - Free Report)

Geron Corporation is a scientific research firm that develops treatment techniques for the health services industries. Geron represents a model of consistency, as it has outperformed our earnings estimates by an average of 20.34%. in each of the past nine quarters. The company’s share price has risen 33.03% over the past twelve weeks, which has prompted Zacks to hand Geron an “A” grade for Momentum.

1 2 3
View single page >> |

Disclosure: Zacks.com contains statements and statistics that have been obtained from sources believed to be reliable but are not guaranteed as to accuracy or completeness. References to any ...

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.
Craig Newman 3 years ago Member's comment

Not any time soon! They have to wait for the Healthcare Bill to pass before traders spend another dime!